Generation Bio Co. (GBIO)

Generation Bio Co. was a biotechnology company based in Cambridge, Massachusetts, that was founded in 2016. It developed genetic medicines built around a non-viral delivery approach. Its platform combined a synthetic, closed-ended DNA construct with lipid nanoparticle delivery, which the company aimed to use to deliver large or complex genetic payloads and, unlike viral vectors, to allow repeat dosing.

The company completed its initial public offering on Nasdaq in June 2020, raising capital to advance preclinical programs in rare and prevalent diseases, including conditions affecting the liver and the immune system. It spent several years building out its platform, manufacturing capabilities and a pipeline of candidates.

Like many clinical-stage gene therapy companies, Generation Bio faced a difficult funding environment after 2022. Its share price fell sharply, it undertook restructurings that reduced headcount, and it reprioritized its pipeline toward a smaller number of programs. In 2025 the board reviewed strategic alternatives as the company worked to preserve its cash.

On December 2025, Generation Bio entered into a merger agreement under which XOMA Royalty Corporation, a company that acquires economic rights to biotech assets, would acquire it. XOMA's plan was to wind down Generation Bio's operations and seek to monetize its delivery platform and programs through licensing or sales rather than develop them itself.

Under the agreement XOMA, through a subsidiary, launched a tender offer for all outstanding shares at $4.2913 per share in cash, plus one non-tradeable contingent value right entitling holders to potential future payments tied to the disposition of the company's assets. The board recommended that stockholders accept the offer.

The tender offer expired at one minute after 11:59 p.m. Eastern time on February 6, 2026, with about 4.72 million shares, roughly 70 percent of those outstanding, tendered. XOMA completed the acquisition on February 9, 2026 through a merger of its subsidiary into Generation Bio, converting remaining shares into the same consideration. Trading on Nasdaq ceased after the close on February 6, and a Form 25 was filed on February 9, 2026.